A startup with no human data just raised $435 million to reverse ageing

Biotech & Longevity 4 min 80 sources

This week the biggest numbers in biotech went to the least proven ideas — a longevity company about to run its first-ever human trial pulled in $435M, while a company with an actual drug got stopped cold by the FDA. The gap between the two is the whole story.

The most striking number in biotech this week wasn’t a survival figure or an effect size. It was a fundraise. NewLimit, a South San Francisco startup trying to rejuvenate old cells, raised $435 million — ahead of running its first trial in humans [1][2].

Read that order again. The money came first. The human test comes later.

What NewLimit is betting on

NewLimit’s idea is genuinely interesting. The body’s cells carry chemical marks — a kind of settings layer sitting on top of the DNA — that drift as we age and seem to push cells toward an older, more worn-out state. The bet is that you can partly reset those marks and make an old cell behave young again, without rewriting the DNA itself [1].

In a dish, and in mice, versions of this “cellular reprogramming” have shown real signals. That’s why serious investors are interested.

But here is the caveat this beat exists to hold: nothing about this has been shown to work, or be safe, in a person. The $435 million is funding the company toward its first clinical trial — the first time the approach meets a human body [2]. Reprogramming carries a known danger: push a cell too far toward “young” and it can start dividing uncontrollably. That’s another word for cancer. Whether NewLimit’s method threads that needle is exactly what an unrun trial cannot yet tell you.

So the size of the cheque tells you how strong the story is. It tells you almost nothing about whether the thing works.

The week’s other big cheques

NewLimit wasn’t alone. The money flowed fast this week:

Roche put $700 million upfront on Nurix’s experimental drug for blood cancers, a “degrader” that tags a faulty protein for the cell’s own garbage disposal [3].
Incyte moved toward a deal worth up to roughly $2 billion for Star, a biotech working on blood disorders [4].
GSK pledged £44.5 million to UK researchers chasing the question of whether scarred livers can heal themselves [5].

Each of these is a wager on a result that hasn’t fully arrived. That’s not a scandal — it’s how drug development is funded. New medicines cost a fortune and take a decade, so somebody has to pay long before anyone knows if it works. Conviction has to run ahead of proof.

The trouble is that conviction and proof are easy to confuse from the outside. A nine-figure raise reads like validation. It isn’t. It’s a bet.

And the week’s cold water

The clearest reminder came from a company moving in the opposite direction. Fulcrum Therapeutics scrapped its sickle-cell disease drug, pociredir, and put itself under “strategic review” after the FDA — the US drug regulator — took a hard line on safety risks [6][7].

This matters because of the contrast. Fulcrum had an actual drug, in actual patients, far past the slide-deck stage. And it still stopped — not because the money dried up, but because the evidence on safety didn’t clear the bar the regulator set [6].

That’s the asymmetry worth carrying. Money can move on a story. The thing that finally decides — the trial, the safety signal, the regulator — only moves on data. One of those happens early and loudly. The other happens late and quietly, and it’s the one that’s real.

The under-covered thread: a real human result, no press release needed

Almost lost under the funding noise was a quieter item that actually cleared the bar the others haven’t reached. Researchers reported a phase 1 trial of an AAV gene therapy — a treatment that uses a harmless virus to ferry a working gene into the body — for an inherited disorder that leaves people with dangerously high cholesterol from birth [8].

A phase 1 trial is the small, first-in-human safety check — a handful of patients, watching mainly for harm, not yet proving the drug works at scale. It’s early. But it’s in people, with a result you can read, which is more than a half-billion-dollar pitch deck can say.

No giant cheque attached. Just a number on a page. That’s the kind of thing that, three quiet phases from now, might matter more than any of this week’s headlines.

02 · Lesson · why it matters

The size of a bet measures belief, not proof

When money or attention rushes toward something, it's tempting to read that as a verdict — surely all those smart people checked. But the size of a bet tells you how strong the story is, not how strong the evidence is. Learning to keep the two apart is one of the quiet skills of not being fooled.

A startup raised $435 million to reverse ageing in human cells. It has not yet tested its idea in a single person.

Pause on how strange that is. Hundreds of millions of dollars, moved by experienced investors who do this for a living — placed before the first piece of human evidence exists. And your instinct, reading it, is to assume the evidence must be there. It must be a sure thing. Look how much money it pulled.

That instinct is the thing to examine.

Two different questions, easy to merge

There are two questions you can ask about any claim, and they feel like one question but aren’t.

The first: how confident are people in this? You can read that off the surface. The size of the fundraise, the loudness of the coverage, the number of experts nodding, the queue of people wanting in. Confidence is visible.

The second: is it actually true? You usually can’t read that off the surface. It takes a test — a real one, the kind that could come back and say no.

The mistake is letting the first answer stand in for the second. Letting the loudness of belief substitute for the existence of proof. We do it constantly, because checking the proof is slow and reading the confidence is instant.

Why belief runs ahead of proof — and has to

Here’s the part that makes it tricky: belief should sometimes run ahead of proof. That’s not a flaw in the system. New medicines take a decade and cost a fortune. If nobody put money down until the proof arrived, the proof would never get made. Someone has to bet early, on the strength of a good story, so the test can happen at all.

So the gap between conviction and evidence isn’t a sign that something’s wrong. It’s normal. It’s how anything ambitious gets built — a company, a career, a marriage, a move across the world. You commit before you can know.

The skill isn’t to refuse all early bets. It’s to remember which one you’re looking at. To not let “a lot of people believe this” quietly become “this has been shown to be true” in your head, when the second thing simply hasn’t happened yet.

The tell: where the deciding actually happens

There’s a reliable way to keep them apart. Ask: what would have to come back and say no — and has it had the chance to?

In the same week the longevity startup raised its $435 million on a promise, another company with a real drug, in real patients, was stopped cold. Not because the money ran out — because the regulator looked at the safety data and didn’t like it. That second thing is what proof looks like: late, quiet, and able to say no.

The loud early bet and the quiet late test live in different rooms. The first room is full of stories and confidence and momentum. The second is where the thing finally gets decided, usually long after the headlines moved on. The first room is the one you hear about. The second is the one that’s real.

And the humbling part

It’s easy to read all this as a tip for spotting other people’s overconfidence — the hyped startup, the breathless news, the crowd that got swept up. But the same gap sits inside your own head, and it’s harder to see there.

You hold beliefs right now that feel settled and proven and are actually just… loud in your mind. Repeated often. Agreed-with by people around you. Backed by the confidence of your own conviction rather than by any test that could have come back and said no. That’s not a failure of intelligence — it’s the default condition of being a person. Most of what any of us “knows” is borrowed conviction wearing the costume of proof.

You can’t run a clean trial on every belief you have; nobody can. But you can hold the small humility of knowing which is which — of feeling the difference between I am sure and this has been tested. The first is a feeling. The second is a fact. Mistaking your certainty for evidence is the oldest way humans fool themselves, and the cure isn’t more certainty. It’s the willingness to ask, quietly, of even your firmest beliefs: has this ever actually had the chance to be wrong?

03 · Lab · your turn

Belief vs Proof

The size of a bet or the loudness of belief measures conviction, not evidence; only a test that could say no measures truth — and the habit is to ask that of your own certainties first.